ANIP - ANI Pharmaceuticals Inc Stock Price, Fair Value and News

61.48USD-2.29 (-3.59%)Market Closed

Market Summary

USD61.48-2.29

Market Closed

-3.59%

ANIP Alerts

2 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

ANIP Stock Price

View Fullscreen

ANIP RSI Chart

ANIP Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

33.41

Price/Sales (Trailing)

2.27

EV/EBITDA

8.92

Price/Free Cashflow

11.21

ANIP Price/Sales (Trailing)

ANIP Profitability

Operating Margin

83.51%

EBT Margin

8.32%

Return on Equity

7.78%

Return on Assets

3.84%

Free Cashflow Yield

8.92%

ANIP Fundamentals

ANIP Revenue

Revenue (TTM)

517.5M

Rev. Growth (Yr)

28.7%

Rev. Growth (Qtr)

4.39%

ANIP Earnings

Earnings (TTM)

35.1M

Earnings Growth (Yr)

1.1K%

Earnings Growth (Qtr)

1.4K%

Breaking Down ANIP Revenue

Last 7 days

-9.6%

Last 30 days

-6.1%

Last 90 days

2.9%

Trailing 12 Months

32.5%

How does ANIP drawdown profile look like?

ANIP Financial Health

Current Ratio

3.95

Debt/Equity

0.63

Debt/Cashflow

0.41

ANIP Investor Care

Shares Dilution (1Y)

16.51%

Diluted EPS (TTM)

1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	517.5M	0	0	0
2023	358.7M	401.4M	449.4M	486.8M
2022	226.1M	251.3M	283.1M	316.4M
2021	213.2M	213.4M	212.5M	216.1M
2020	203.4M	197.5M	199.2M	208.5M
2019	208.0M	215.1M	215.7M	206.5M
2018	186.7M	189.2M	191.7M	201.6M
2017	144.7M	158.1M	167.8M	176.8M
2016	78.1M	89.9M	108.5M	128.6M
2015	63.9M	76.7M	79.3M	76.3M
2014	35.4M	35.9M	45.5M	56.0M
2013	17.8M	18.7M	21.5M	30.1M
2012	5.4M	10.4M	15.4M	20.4M
2011	2.0M	1.5M	944.9K	435.2K
2010	1.6M	1.9M	2.2M	2.5M
2009	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ANI Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	gassert chad	sold	-1,332,400	66.62	-20,000	svp - corp. dev. & strategy
Apr 19, 2024	shanmugam muthusamy	sold	-1,095,440	65.17	-16,809	head of r&d, coo-novitium ops
Apr 18, 2024	shanmugam muthusamy	sold	-677,287	64.98	-10,423	head of r&d, coo-novitium ops
Apr 17, 2024	shanmugam muthusamy	sold	-622,608	65.4	-9,520	head of r&d, coo-novitium ops
Apr 16, 2024	shanmugam muthusamy	sold	-386,211	66.2	-5,834	head of r&d, coo-novitium ops
Apr 15, 2024	shanmugam muthusamy	sold	-491,771	66.33	-7,414	head of r&d, coo-novitium ops
Apr 12, 2024	cook meredith	sold	-16,947	67.79	-250	sr. vp, general counsel & sec.
Apr 10, 2024	carey stephen p.	sold (taxes)	-303,597	66.96	-4,534	svp & cfo
Apr 10, 2024	marken james g.	sold (taxes)	-187,421	66.96	-2,799	svp ops & prod dev
Apr 01, 2024	gassert chad	sold	-1,345,000	67.25	-20,000	svp - corp. dev. & strategy

Which funds bought or sold ANIP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-0.52	502,323	2,534,490	0.01%
May 16, 2024	JANE STREET GROUP, LLC	added	373	3,872,190	4,656,110	-%
May 16, 2024	HANCOCK WHITNEY CORP	new	-	360,306	360,306	0.01%
May 16, 2024	Virtus Investment Advisers, Inc.	unchanged	-	172,342	851,612	0.61%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	1.46	239,136	1,118,180	-%
May 15, 2024	ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	new	-	581,000	581,000	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	unchanged	-	217,349	1,074,000	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	added	0.06	73,509	363,564	-%
May 15, 2024	Gotham Asset Management, LLC	reduced	-16.39	24,665	535,758	0.01%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-31.74	-1,383,840	8,210,290	-%

Are Funds Buying or Selling ANIP?

Are funds buying ANIP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANIP

No. of Funds

Unveiling ANI Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 14, 2024	meridian venture partners ii gp, l.p.	6.7%	1,419,381	SC 13D/A
Feb 13, 2024	vanguard group inc	6.31%	1,288,972	SC 13G
Feb 12, 2024	rubric capital management lp	5.51%	1,125,000	SC 13G
Jan 23, 2024	blackrock inc.	12.4%	2,524,660	SC 13G/A
Jan 17, 2024	esjay llc	4.6%	932,620	SC 13D/A
Dec 18, 2023	meridian venture partners ii gp, l.p.	8.1%	1,644,381	SC 13D/A
Dec 05, 2023	esjay llc	4.8%	982,620	SC 13D/A
Aug 18, 2023	meridian venture partners ii gp, l.p.	9.0%	1,819,259	SC 13D/A
Jan 26, 2023	blackrock inc.	11.4%	1,983,237	SC 13G/A
Jan 20, 2023	blackrock inc.	11.4%	1,983,237	SC 13G/A

Recent SEC filings of ANI Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	144	Notice of Insider Sale Intent
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	4	Insider Trading
May 15, 2024	144	Notice of Insider Sale Intent
May 14, 2024	144	Notice of Insider Sale Intent
May 14, 2024	8-K	Current Report
May 13, 2024	4	Insider Trading

Peers (Alternatives to ANI Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

ANI Pharmaceuticals Inc News

Latest updates

ANI Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.4%	137	132	132	117	107	94.00	84.00	74.00	64.00	61.00	52.00	49.00	55.00	57.00	53.00	48.00	50.00	48.00	51.00	54.00	53.00
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	25.00	20.00	21.00	22.00	18.00	15.00	16.00	15.00
Costs and Expenses	-6.3%	117	125	114	104	97.00	92.00	89.00	87.00	84.00	85.00	56.00	64.00	51.00	57.00	50.00	60.00	58.00	53.00	44.00	45.00	48.00
S&GA Expenses	8.0%	48.00	44.00	42.00	39.00	36.00	33.00	30.00	32.00	29.00	31.00	17.00	19.00	18.00	14.00	16.00	21.00	14.00	14.00	14.00	14.00	13.00
R&D Expenses	6.5%	11.00	10.00	11.00	7.00	6.00	5.00	8.00	4.00	5.00	3.00	2.00	3.00	3.00	4.00	3.00	3.00	6.00	5.00	5.00	6.00	4.00
EBITDA Margin	16.8%	0.27*	0.23*	0.23*	0.18*	0.12*	0.05*	-0.05*	-0.05*	-0.08*	0.00*	0.12*	0.15*	0.17*	0.12*	0.10*	0.11*	0.19*	0.26*	0.32*	0.32*	0.32*
Interest Expenses	-0.7%	8.00	8.00	8.00	11.00	4.00	7.00	3.00	6.00	6.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	0.00
Income Taxes	3802.9%	7.00	-0.19	2.00	-1.00	1.00	-1.47	-3.62	-3.90	-5.77	-6.72	-2.68	-4.04	-0.01	1.00	-0.37	-1.40	-2.90	-2.82	0.00	-0.65	0.00
Earnings Before Taxes	2575.3%	25.00	1.00	12.00	5.00	2.00	-5.73	-12.22	-18.82	-25.90	-30.85	-7.13	-18.15	0.00	-2.37	0.00	-13.80	-9.86	-7.66	4.00	6.00	1.00
EBT Margin	103.8%	0.08*	0.04*	0.03*	-0.03*	-0.10*	-0.20*	-0.31*	-0.33*	-0.36*	-0.26*	-0.13*	-0.10*	-0.08*	-0.12*	-0.16*	-0.14*	-0.04*	0.02*	0.08*	0.10*	0.09*
Net Income	1441.2%	18.00	1.00	10.00	6.00	1.00	-4.24	-8.60	-14.92	-20.13	-24.14	-4.45	-14.11	0.00	-3.63	0.00	-12.34	-7.01	-4.83	4.00	7.00	0.00
Net Income Margin	76.0%	0.07*	0.04*	0.03*	-0.01*	-0.07*	-0.15*	-0.24*	-0.25*	-0.28*	-0.20*	-0.10*	-0.08*	-0.07*	-0.11*	-0.12*	-0.10*	-0.01*	0.03*	0.08*	0.08*	0.07*
Free Cashflow	-67.8%	14.00	42.00	30.00	18.00	19.00	-7.54	1.00	-12.80	-20.89	-12.54	-5.97	-0.69	20.00	-7.82	-3.37	20.00	0.00	3.00	20.00	3.00	13.00

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.1%	915	904	890	859	765	760	739	751	745	772	470	480	464	461	463	465	482	457	457	447	434
Current Assets	4.0%	541	520	497	459	365	344	309	322	301	322	191	192	183	170	166	157	159	188	182	169	152
Cash Equivalents	3.4%	229	221	193	162	68.00	48.00	56.00	63.00	77.00	100	15.00	24.00	25.00	8.00	18.00	28.00	20.00	62.00	60.00	41.00	38.00
Inventory	2.4%	114	111	107	104	104	105	96.00	93.00	83.00	82.00	62.00	68.00	60.00	61.00	59.00	53.00	53.00	48.00	46.00	45.00	42.00
Net PPE	8.8%	49.00	45.00	44.00	44.00	43.00	43.00	43.00	44.00	53.00	53.00	40.00	40.00	41.00	41.00	40.00	40.00	40.00	41.00	40.00	39.00	38.00
Goodwill	0%	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	28.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00
Liabilities	-2.0%	438	447	435	425	426	422	402	414	399	413	279	288	260	265	267	274	281	244	244	239	235
Current Liabilities	-5.9%	137	145	134	123	126	99.00	82.00	96.00	80.00	88.00	85.00	89.00	83.00	79.00	76.00	79.00	79.00	62.00	171	167	165
Long Term Debt	-0.1%	285	285	285	285	285	286	286	286	286	287	186	190	169	172	175	178	188	176	65.00	66.00	67.00
LT Debt, Current	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	16.00	15.00	14.00	13.00	13.00	12.00	12.00	10.00	4.00	4.00	3.00
LT Debt, Non Current	-100.0%	-	285	285	285	285	286	286	286	286	287	186	190	169	172	175	178	188	176	65.00	66.00	67.00
Shareholder's Equity	4.4%	452	433	430	495	408	314	399	395	321	388	191	192	204	0.00	195	191	201	213	213	208	200
Retained Earnings	22.2%	-62.33	-80.13	-80.88	-90.41	-96.25	-97.29	-92.60	-83.63	-68.30	-47.76	-23.44	-18.99	-4.89	-4.97	-1.34	-1.77	11.00	18.00	22.00	19.00	12.00
Additional Paid-In Capital	1.9%	524	514	507	495	408	404	399	395	391	388	222	219	216	214	212	209	204	201	197	195	190
Accumulated Depreciation	-	-	-	-	-	27.00	33.00	30.00	27.00	25.00	23.00	21.00	20.00	19.00	18.00	-	-	-	-	-	-	-
Shares Outstanding	6.1%	19.00	18.00	18.00	17.00	16.00	16.00	16.00	16.00	16.00	13.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Float	-	-	-	-	824	-	-	-	373	-	-	-	348	-	-	-	316	-	-	-	658	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-59.2%	18,269	44,740	32,169	20,626	21,424	-4,400	3,623	-11,484	-18,942	-12,185	-5,402	241	20,668	-5,709	-1,614	20,880	1,710	4,803	21,793	4,744	14,291
Share Based Compensation	23.4%	6,934	5,621	5,444	5,249	4,338	3,737	3,869	3,756	3,237	2,968	2,808	2,844	1,869	2,393	2,383	5,736	2,424	2,444	2,470	2,593	1,710
Cashflow From Investing	286.9%	8,933	-4,779	-4,553	-6,826	-2,353	-3,142	-9,814	-604	-2,178	-82,213	-583	-21,950	-737	-2,119	-5,809	-2,848	-57,546	-1,374	-1,932	-3,958	-20,285
Cashflow From Financing	-65.5%	-19,726	-11,918	3,755	80,150	-4,548	-508	-911	-1,437	-2,270	179,444	-3,022	20,898	-2,725	-2,208	-2,378	-10,744	13,891	-766	-770	1,580	1,206
Dividend Payments	-100.0%	-	406	406	407	406	407	406	407	405	190	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	3649.4%	8,661	231	670	537	3,549	119	239	483	1,118	1.00	73.00	468	348	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ANIP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Revenues	$ 137,430	$ 106,786
Operating Expenses
Cost of sales (excluding depreciation and amortization)	49,157	37,708
Research and development	10,511	5,924
Selling, general, and administrative	48,021	36,468
Depreciation and amortization	14,686	14,700
Contingent consideration fair value adjustment	90	961
Restructuring activities	0	1,130
Gain on sale of building	(5,347)	0
Total Operating Expenses, net	117,118	96,891
Operating Income	20,312	9,895
Other Income (Expense), net
Unrealized gain on investment in equity securities	9,655	0
Interest expense, net	(4,600)	(7,696)
Other expense, net	(32)	(34)
Income Before Income Tax Expense	25,335	2,165
Income tax expense	7,128	726
Net Income	18,207	1,439
Dividends on Series A Convertible Preferred Stock	(406)	(406)
Net Income Available to Common Shareholders	$ 17,801	$ 1,033
Basic and Diluted Income Per Share:
Basic Income (Loss) Per Share (in dollars per share)	$ 0.84	$ 0.06
Diluted Income (Loss) Per Share (in dollars per share)	$ 0.82	$ 0.06
Basic Weighted-Average Shares Outstanding (in shares)	19,099	16,392
Diluted Weighted-Average Shares Outstanding (in shares)	19,422	16,531

ANIP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 228,597	$ 221,121
Accounts receivable, net of $91,825 and $97,262 of adjustments for chargebacks and other allowances at March 31, 2024 and December 31, 2023, respectively	172,418	162,079
Inventories	113,837	111,196
Assets held for sale	0	8,020
Prepaid expenses and other current assets	16,050	17,400
Investment in equity securities	9,655	0
Total Current Assets	540,557	519,816
Non-current Assets
Property and equipment, net	48,526	44,593
Deferred tax assets, net of deferred tax liabilities and valuation allowance	87,607	90,711
Intangible assets, net	196,044	209,009
Goodwill	28,221	28,221
Derivatives and other non-current assets	13,569	12,072
Total Assets	914,524	904,422
Current Liabilities
Current debt, net of deferred financing costs	850	850
Accounts payable	49,430	36,683
Accrued royalties	15,475	16,276
Accrued compensation and related expenses	9,526	23,786
Accrued government rebates	9,509	12,168
Income taxes payable	11,402	8,164
Returned goods reserve	32,853	29,678
Current contingent consideration	414	12,266
Accrued expenses and other	7,430	5,606
Total Current Liabilities	136,889	145,477
Non-current Liabilities
Non-current debt, net of deferred financing costs and current component	284,607	284,819
Non-current contingent consideration	11,160	11,718
Other non-current liabilities	5,055	4,809
Total Liabilities	437,711	446,823
Commitments and Contingencies (Note 12)
Mezzanine Equity
Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at March 31, 2024 and December 31, 2023	24,850	24,850
Stockholders’ Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 21,373,266 shares issued and 20,980,307 outstanding at March 31, 2024; 20,730,896 shares issued and 20,466,953 shares outstanding at December 31, 2023	2	2
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Treasury stock, 392,959 shares of common stock, at cost, at March 31, 2024 and 263,943 shares of common stock, at cost, at December 31, 2023	(18,742)	(10,081)
Additional paid-in capital	523,628	514,103
Accumulated deficit	(62,331)	(80,132)
Accumulated other comprehensive income, net of tax	9,406	8,857
Total Stockholders’ Equity	451,963	432,749
Total Liabilities, Mezzanine Equity, and Stockholders’ Equity	$ 914,524	$ 904,422

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

CEO	Mr. Nikhil Lalwani
WEBSITE	anipharmaceuticals.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	600

ANI Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ANI Pharmaceuticals Inc? What does ANIP stand for in stocks?

ANIP is the stock ticker symbol of ANI Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ANI Pharmaceuticals Inc (ANIP)?

As of Fri May 17 2024, market cap of ANI Pharmaceuticals Inc is 1.17 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIP stock?

You can check ANIP's fair value in chart for subscribers.

What is the fair value of ANIP stock?

You can check ANIP's fair value in chart for subscribers. The fair value of ANI Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ANI Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ANI Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ANIP is over valued or under valued. Whether ANI Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ANI Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIP.

What is ANI Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ANIP's PE ratio (Price to Earnings) is 33.41 and Price to Sales (PS) ratio is 2.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ANI Pharmaceuticals Inc's stock?

In the past 10 years, ANI Pharmaceuticals Inc has provided 0.08 (multiply by 100 for percentage) rate of return.